Literature DB >> 24807065

Endothelial keratoplasty in children.

Hamed M Anwar1, Alaa El-Danasoury.   

Abstract

PURPOSE OF REVIEW: Descemet stripping endothelial keratoplasty has superseded penetrating keratoplasty (PKP) in adults as the procedure of choice for treating endothelial dysfunction, but endothelial keratoplasty despite the multitude of advantages has undergone a much slower adoption in pediatric patients. This review focuses on the recent advances made in the field of pediatric endothelial keratoplasty and the associated surgical challenges. RECENT
FINDINGS: Pediatric endothelial keratoplasty does not require as many sutures as PKP, and the wound size is smaller and more stable. Endothelial keratoplasty grafts clear faster, possibly allowing for a more effective management of amblyopia. Visual outcomes appear to be comparable with PKP but with a lower complication rate.
SUMMARY: As corneal surgeons grow more and more familiar with the nuances of pediatric endothelial keratoplasty, our understanding of this procedure will become more complete. The limited data available suggest that endothelial keratoplasty is a suitable surgical alternative to PKP in children.

Entities:  

Mesh:

Year:  2014        PMID: 24807065     DOI: 10.1097/ICU.0000000000000063

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  3 in total

Review 1.  [Treatment of corneal endothelial disorders by DMEK and UT-DSAEK. Indications, complications, results and follow-up].

Authors:  B Bachmann; F Schaub; C Cursiefen
Journal:  Ophthalmologe       Date:  2016-03       Impact factor: 1.059

2.  [Pediatric corneal surgery and corneal transplantation].

Authors:  B Bachmann; G Avgitidou; S Siebelmann; C Cursiefen
Journal:  Ophthalmologe       Date:  2015-02       Impact factor: 1.059

Review 3.  Pediatric endothelial keratoplasty: a systematic review and individual participant data meta-analysis.

Authors:  Masomeh Mohebbi; Mohammad Mehrpour; Amin Dehghani Sanij; Nader Mohammadi; Masoud Mirghorbani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-10-28       Impact factor: 3.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.